What is Bonesupport?
Bonesupport AB specializes in the development and commercialization of advanced orthobiologic solutions, primarily focusing on injectable synthetic bone graft substitutes. The company's core technology platform utilizes calcium sulfate and hydroxyapatite formulations, which provide both structural integrity and biological support for natural bone regeneration. A key differentiator in their product portfolio is the integration of local antibiotic delivery, which allows surgeons to treat bone infections, such as osteomyelitis, while simultaneously facilitating bone healing. This dual-action capability positions the company as a critical player in the orthopedic and trauma surgery markets, where clinical evidence and patient outcomes are paramount.
How much funding has Bonesupport raised?
Bonesupport has raised a total of $256M across 5 funding rounds:
Unspecified
$15M
Unspecified
$120M
Unspecified
$70M
Private Equity
$14M
Private Equity
$37M
Unspecified (2006): $15M with participation from Ferd Venture, Teknoinvest, and Innovations Kapital
Unspecified (2011): $120M led by HealthCap Partners and Industrifonden
Unspecified (2012): $70M supported by Lundbeckfond Ventures, Industrifonden, and HealthCap Partners
Private Equity (2015): $14M, investors not publicly disclosed
Private Equity (2016): $37M backed by HealthCap Partners, Lundbeckfond Ventures, Industrifonden, Kreos Capital, and AP3
Key Investors in Bonesupport
HealthCap Partners
HealthCap is a private equity firm specializing in creative growth capital and real estate solutions for the strategic needs of the healthcare industry.
Industrifonden
Industrifonden is a Swedish venture capital fund that invests in unique, scalable innovations aimed at improving society through breakthrough technologies and science.
Lundbeckfond Ventures
The Lundbeck Foundation is a commercial research foundation which awards grants to Danish-based biomedical research groups, with their main focus being the field of brain research.
What's next for Bonesupport?
Looking ahead, Bonesupport is well-positioned to leverage its recent capital influx to expand its international footprint and deepen its clinical research initiatives. The company's strategic focus remains on advancing its proprietary platform to address increasingly complex bone defects and infections. By maintaining strong partnerships with orthopedic surgeons and healthcare institutions, Bonesupport is poised to continue its trajectory of innovation, potentially setting new benchmarks for musculoskeletal care. The firm's ability to combine structural support with therapeutic delivery remains a significant competitive advantage as it scales operations across Europe, North America, and emerging international markets.
See full Bonesupport company page
